RxDoctor Payments Data

Sally Markell, NP

Nurse Practitioner · Washington, DCNPI 1851720783

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 27 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 13 manufacturers reported payments, led by Pfizer at 24.9% of the total. 2025 is the largest year on record at $263, 3.4 times the $78 reported in 2021.

$554in general payments, 2019–2025

Across 27 payments — averaging $20.52 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Pfizer$138
  • Novo Nordisk$114
  • Lilly USA, LLC$66
  • Amgen$40
  • Daiichi Sankyo Inc.$34
  • Exact Sciences$30
  • plus $133 from 7 others

What the payments were for

  • Food & beverage$554100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$554 in reported general payments places this provider in the 80th percentile of 224 nurse practitioner providers in District of Columbia.

See all nurse practitioner providers in District of Columbia

Medicare billing

Part B allowed, 2024
$9,929
Medicare patients
78
Services billed
95

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide17$25,240
Levothyroxine Sodium75$1,135
SynthroidLevothyroxine Sodium11$1,063
Pravastatin Sodium37$1,041
Atorvastatin Calcium100$700
Duloxetine Hcl14$618
Pantoprazole Sodium15$523
Metoprolol Succinate21$475
Amlodipine Besylate59$419
Losartan Potassium45$344
Lisinopril57$339
Rosuvastatin Calcium27$325
Clonazepam16$321
Venlafaxine Hcl ErVenlafaxine Hcl12$315
Simvastatin24$314

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$114$25,24017 claims
PfizerPaxlovid$138$015 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 224 nurse practitioner providers in District of Columbia.

Other nurse practitioner in Washington

See the full list for District of Columbia

Where these figures come from

Is this you, or does something look wrong? →